GlassScriptPhysician profile
Nicholas Wade Salupo
NPI 1619402617
$1,119.08
in general payments reported to CMS, 2019-2025
18 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.86 · 2022: $125 · 2023: $110 · 2024: $491 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.24 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $133.73 | 2025 | Veltassa |
| Veloxis Pharmaceuticals, INC. | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.87 | 2024 | Airsupra |
| Genzyme Corporation | $100.44 | 2024 | |
| Alexion Pharmaceuticals, INC. | $99.99 | 2024 | Soliris |
| Otsuka America Pharmaceutical, INC. | $99.15 | 2024 | Rexulti |
| Abbvie INC. | $87.46 | 2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.31 | 2024-2025 | Jardiance |
| Nxstage Medical, INC. | $43.34 | 2025 | Nxstage System One, Nxstage Cartridge Express, Nxstage Pureflow Solution |
| Amgen INC. | $38.51 | 2024-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $37.72 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $37.43 | 2025 | |
| Mallinckrodt Hospital Products INC. | $32.23 | 2025 | Terlivaz |
| Outset Medical INC | $22.88 | 2023 | |
| Ardelyx, INC. | $16.76 | 2025 | Ibsrela |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $16.43 | 2025 | Tarpeyo |
| Travere Therapeutics, INC. | $15.98 | 2025 | |
| Adamas Pharmaceuticals, INC. | $15.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Salupo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.